# Danaher vs Vertex Pharmaceuticals: stocks compared

URL: https://funkfolio.com/compare/dhr-vs-vrtx

> Danaher ($158.8B, P/E 38.1) and Vertex Pharmaceuticals ($135.4B, P/E 34.6) compared: size, valuation, margins, debt, cash and price change.

---

## Danaher vs Vertex Pharmaceuticals

Danaher (DHR), health care, and Vertex Pharmaceuticals (VRTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Danaher is worth $158.8B on the stock market and Vertex Pharmaceuticals $135.4B: Danaher is valued at 17% more. Danaher trades at 38.1 times earnings and Vertex Pharmaceuticals at 34.6; operating margins in their latest fiscal years were 19.1% and 34.8%. Over the past year Danaher's share price has moved +1.95% and Vertex Pharmaceuticals's +23.5%.

### Key facts

- **Danaher market value:** $158.8B
- **Vertex Pharmaceuticals market value:** $135.4B
- **Danaher P/E:** 38.1
- **Vertex Pharmaceuticals P/E:** 34.6
- **Danaher revenue:** $24.6B FY to 2025-12-31
- **Vertex Pharmaceuticals revenue:** $12B FY to 2025-12-31
- **Superinvestors holding both:** 1

Market values as of 18 Nov 2026, 04:26 UTC.

Danaher vs Vertex Pharmaceuticals: every measure side by side

| Measure | Danaher | Vertex Pharmaceuticals |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $158.8B higher | $135.4B lower |
| Revenue | $24.6B higher | $12B lower |
| Earnings | $3.6B lower | $4B higher |
| Employees | 58,000 higher | 6,400 lower |
| Total assets | $83.5B higher | $25.6B lower |
| Valuation |  |  |
| P/E | 38.1 higher | 34.6 lower |
| P/S | 6.5 lower | 11.3 higher |
| P/B | 3.0 lower | 6.5 higher |
| Dividend yield | 0.66% higher | 0.00% lower |
| Profitability |  |  |
| Operating margin | 19.1% lower | 34.8% higher |
| Balance sheet |  |  |
| Net assets | $52.5B higher | $18.7B lower |
| Total liabilities | $30.9B higher | $7B lower |
| Total debt | $18.4B | — |
| Cash on hand | $4.6B lower | $5.1B higher |
| Price change |  |  |
| Today | -1.80% lower | -0.67% higher |
| 1 year | +1.95% lower | +23.5% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Danaher 102.4, Vertex Pharmaceuticals 123.1.

- Danaher (DHR)
- Vertex Pharmaceuticals (VRTX)

Danaher and Vertex Pharmaceuticals share prices over one year, rebased to 100: Danaher ends at 102.4, Vertex Pharmaceuticals at 123.1.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | DHR | VRTX |
| --- | --- | --- |
| Nov 28, 2025 | 102.9 | 99.9 |
| Dec 31, 2025 | 103.8 | 104.5 |
| Jan 30, 2026 | 99.3 | 108.3 |
| Feb 27, 2026 | 95.6 | 114.5 |
| Mar 31, 2026 | 86.0 | 102.9 |
| Apr 30, 2026 | 81.2 | 98.5 |
| May 29, 2026 | 82.9 | 103.1 |
| Jun 30, 2026 | 86.4 | 114.4 |
| Jul 31, 2026 | 88.5 | 109.9 |
| Aug 31, 2026 | 96.9 | 125.5 |
| Sep 30, 2026 | 100.5 | 120.5 |
| Oct 30, 2026 | 105.3 | 128.8 |
| Nov 17, 2026 | 102.4 | 123.1 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (1)

- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.3% / 0.2%

#### Danaher only (18)

- [Wallace Weitz](https://funkfolio.com/gurus/wallace-weitz) 7.0%
- [Eric Bannasch](https://funkfolio.com/gurus/eric-bannasch) 4.8%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 4.4%
- [Doug Silverman](https://funkfolio.com/gurus/doug-silverman) 2.3%
- [Dan Loeb](https://funkfolio.com/gurus/dan-loeb) 2.2%
- [Daniel Sundheim](https://funkfolio.com/gurus/daniel-sundheim) 2.1%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 1.6%
- [Steven Romick](https://funkfolio.com/gurus/steven-romick) 1.5%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 1.2%
- [Chase Coleman](https://funkfolio.com/gurus/chase-coleman) 0.4%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.3%
- [Primecap team](https://funkfolio.com/gurus/primecap) 0.3%
- [Louis Bacon](https://funkfolio.com/gurus/louis-bacon) 0.2%
- [Stanley Druckenmiller](https://funkfolio.com/gurus/stanley-druckenmiller) 0.2%
- [Bill Gates](https://funkfolio.com/gurus/gates-foundation) 0.2%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.2%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) &lt;0.1%

#### Vertex Pharmaceuticals only (4)

- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 1.1%
- [Jim Simons (1938–2024)](https://funkfolio.com/gurus/jim-simons) 0.3%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.1%
- [Baillie Gifford team](https://funkfolio.com/gurus/baillie-gifford) 0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Danaher / Vertex Pharmaceuticals). [Who owns DHR](https://funkfolio.com/stock/DHR/superinvestors) · [Who owns VRTX](https://funkfolio.com/stock/VRTX/superinvestors)

### More on Danaher

- [Danaher (DHR) stock page](https://funkfolio.com/stock/DHR)
- [Danaher market cap](https://funkfolio.com/stock/DHR/market-cap)
- [Danaher revenue](https://funkfolio.com/stock/DHR/revenue)
- [Danaher P/E ratio](https://funkfolio.com/stock/DHR/pe-ratio)
- [Danaher operating margin](https://funkfolio.com/stock/DHR/operating-margin)
- [Danaher total debt](https://funkfolio.com/stock/DHR/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Vertex Pharmaceuticals

- [Vertex Pharmaceuticals (VRTX) stock page](https://funkfolio.com/stock/VRTX)
- [Vertex Pharmaceuticals market cap](https://funkfolio.com/stock/VRTX/market-cap)
- [Vertex Pharmaceuticals revenue](https://funkfolio.com/stock/VRTX/revenue)
- [Vertex Pharmaceuticals P/E ratio](https://funkfolio.com/stock/VRTX/pe-ratio)
- [Vertex Pharmaceuticals operating margin](https://funkfolio.com/stock/VRTX/operating-margin)
- [Vertex Pharmaceuticals total debt](https://funkfolio.com/stock/VRTX/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Danaher against its closest peers

- [Danaher vs Pfizer](https://funkfolio.com/compare/dhr-vs-pfe)
- [Danaher vs Intuitive Surgical](https://funkfolio.com/compare/dhr-vs-isrg)
- [Danaher vs Novo Nordisk](https://funkfolio.com/compare/dhr-vs-nvo)
- [Danaher vs Abbott Laboratories](https://funkfolio.com/compare/abt-vs-dhr)

#### Vertex Pharmaceuticals against its closest peers

- [Vertex Pharmaceuticals vs Medtronic](https://funkfolio.com/compare/mdt-vs-vrtx)
- [Vertex Pharmaceuticals vs Bristol-Myers Squibb](https://funkfolio.com/compare/bmy-vs-vrtx)
- [Vertex Pharmaceuticals vs Intuitive Surgical](https://funkfolio.com/compare/isrg-vs-vrtx)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Danaher or Vertex Pharmaceuticals?**

By market value, Danaher is the larger: $158.8B against $135.4B for Vertex Pharmaceuticals. By revenue in its latest fiscal year, Danaher is the larger: $24.6B against $12B for Vertex Pharmaceuticals.

**Which has the higher P/E ratio?**

Danaher: 38.1, against 34.6 for Vertex Pharmaceuticals. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Vertex Pharmaceuticals: 34.8%, against 19.1% for Danaher. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has the higher dividend yield?**

Danaher: 0.66%, against 0.00% for Vertex Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which superinvestors own both Danaher and Vertex Pharmaceuticals?**

In their latest 13F filings, Israel Englander holds both.

### Cite this page

Funkfolio, “Danaher vs Vertex Pharmaceuticals”, data as of 18 November 2026. https://funkfolio.com/compare/dhr-vs-vrtx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
